echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: 5-aza+HSCT can significantly improve the survival rate of elderly patients with MDS

    J Clin Oncol: 5-aza+HSCT can significantly improve the survival rate of elderly patients with MDS

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In contrast to 5-azacytidine (5-aza), allogeneic stem cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndrome (MDS), but treatment-related mortality (TRM) limits its use MDS is widely used in elderly patients
    .

    stem cell

    This is a prospective multi-center study comparing the prognosis of HSCT after 5-aza pretreatment with continuous 5-aza treatment in high-risk MDS patients aged 55-70 years
    .

    The prognosis of HSCT after 5-aza pretreatment and continuous 5-aza treatment was compared in 55-70-year-old high-risk MDS patients

    A total of 190 MDS patients (median age 63 years) were recruited
    .


    After receiving 4-6 courses of 5-aza, the test patients received HLA-compatible HSCT under reduced intensity conditions.


    Twenty-eight patients were excluded from the analysis because they did not meet the inclusion criteria (n=20), died (n=2), withdrew from the study (n=5), and for unknown reasons (n=1)
    .


    162 patients underwent 5-aza induction therapy, but due to disease progression (n=26), death (n=12) or other reasons (n=16), only 108 (67%) patients were eligible for follow-up HSCT ( n=81) or continue 5-aza treatment


    PFS and OS of patients with two treatment strategies

    PFS and OS of patients with two treatment strategies

    7% of patients died during 5-aza treatment before grouping
    .


    The cumulative incidence of TRM one year after HSCT was 19%


    The 3-year event-free survival rate and overall survival rate after 5-aza+HSCT were 34% (95% CI 22-47) and 50% (95% CI 39-61), respectively; and 3 years after continuous 5-aza treatment The annual event-free survival rate and overall survival rate were 0% (p<0.


    In summary, in elderly patients with MDS, reduced-intensity conditional HSCT can significantly improve the event-free survival rate compared with continuous 5-aza therapy
    .


    Disease progression, death and adverse reactions are the main reasons why these patients cannot switch from 5-aza treatment to HSCT


    In elderly patients with MDS, reduced-intensity conditioned HSCT can significantly improve the event-free survival rate compared to continuous 5-aza therapy.


    Original source:

    Nicolaus Kroger, et al.


    omparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study) in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.